Cathepsin E as a marker of colon cancer



Elevated levels of cathepsin E (catE) are demonstrated to be diagnostic of intestinal forms of cancer, such as colorectal cancer. Elevated levels of cathepsin E (catE, monomeric forms) are demonstrated to be detectable in the urine of animals having colorectal cancer, and a diagnostic/screening method for identifying and/or detecting colorectal in an animal from a urine sample is provided. Specific tissue immunohistochemcial staining for catE (monomeric forms) in dysplastic tissue is also disclosed, and is shown to correlate with the level of dysplastic lesion severity. Hence, a method for determining and identifying dysplastic lesion severity is provided. Cathepsin E mRNA transcription and expression levels are also demonstrated to be upregulated in dysplastic tissue, relative to non-dysplastic tissue. Hence, a method for transcriptionally profiling an animal to monitor the progression of colorectal disease is provided.


Attribute NameValues
  • Cathepsin E as a marker of colon cancer

Patent Number
  • US 7892750 B2

  • Rudolph M. Navari

  • Mary Prorok

  • Francis J. Castellino

Inventor From Local Institution
  • Rudolph M. Navari

  • Francis J. Castellino

  • Mary Prorok

Other Application
  • 11/312,780

  • 12

Classification (US Patent)
  • 435/7.1; 530/350; 530/387.1;

Cooperative Patent Classification codes
  • G01N 33/573 (20130101); G01N 33/57419 (20130101); G01N 2333/948 (20130101)

International Patent Classification codes
  • G01N 33/53 (20060101)

  • eng

Date Issued
  • 2011-02-22

  • United States Patent and Trademark Office

  • University of Notre Dame Du Lac

Record Visibility and Access Public
Content License
Departments and Units
Member of


Collections Featuring this Patent
Notre Dame Patents


Please Note: You may encounter a delay before a download begins. Large or infrequently accessed files can take several minutes to retrieve from our archival storage system.